Rite Aid

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through following segments: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Philadelphia, PA.

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rite Aid is a drugstore chain that offers prescription medications, over-the-counter drugs, and health and wellness products. Rite Aid is reshaping the concept of a modern pharmacy by catering to customer demands through various convenient channels, including retail and delivery pharmacy services. Additionally, the company's offerings extend to services provided by its wholly-owned subsidiaries, namely Elixir, Bartell Drugs, and Health Dialog. Elixir, Rite Aid’s pharmacy benefits and services company, encompasses accredited mail and specialty pharmacies, prescription discount programs, and an advanced adjudication platform. These components combine to provide exceptional member experiences and substantial cost savings. Furthermore, Health Dialog delivers healthcare coaching and disease management services through interactive live online sessions and phone-based health services.

Rite Aid is a health products and services company with 2,400 locations across 17 states.

The company's omnichannel business includes digital, retail, and delivery touchpoints. Rite Aid is a top 20 seller of speciality medications, per its investor website.

In addition to its retail business, Rite Aid owns a pharmacy benefits subdivision (Elixir) and a personalized health services and coaching arm, Health Dialog, which has served 10MM members as of May 2022.

The company has reported $1.85 billion of liquidity with no debt maturities until 2025. According to its investor website, Rite Aid expects to be free cash flow (FCF) positive in FY23.

In Q2 2022, Rite Aid shared a three-part growth strategy aimed at deepening market share, expanding into new markets, and creating new offerings.

To grow the current business, Rite Aid is aiming to increase its e-commerce and digital sales, refresh its loyalty program, and grow its specialty pharmacy offering, which focuses on serving customers with complex health conditions.

New market expansion plans include increasing Rite Aid's footprint of "small format" pharmacies in underserved communities and implementing "store within a store" partnerships.

Rite Aid also aims to grow via new offerings, such as expanded health plan and health system clinical services, a pharmacy benefit manager (PBM) as a service offering, and new strategic partnerships.

Rite Aid Investor Relations

*This is not investment advice.

Rite Aid Corporation (NYSE: RAD) reported second-quarter earnings of 12 cents per share on Thursday, beating the analyst consensus estimate of 7 cents by 71.43%.

Rite Aid Reports Mixed Q2 Earnings, New CEO Says Pharmacy Chain 'Acting With Urgency'

Rite Aid's stock surged in pre-market trading Thursday after reporting better-than-expected earnings under new CEO Heyward Donigan.

Rite Aid jumped about 9% after reporting better-than-expected earnings

Rite Aid (RAD) delivered earnings and revenue surprises of 50.00% and -0.91%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?

Rite Aid (RAD) Surpasses Q2 Earnings Estimates

Shares of Rite Aid Corp. RAD, +0.00% shot up 4% in premarket trading Thursday, after the drugstore chain reported an adjusted fiscal second-quarter profit that beat expectations, while revenue fell a bit shy.

Rite Aid's stock jumps after profit beat, but revenue falls shy

On Thursday, Sept. 26, Rite Aid Corporation (NYSE: RAD) will release its latest earnings report.

Earnings Preview: Rite Aid

With Rite Aid reporting Q2 earnings on Thursday, all eyes will focus on the pharmacy retailer’s forward guidance. Unfortunately, that might not be a good thing for RAD stock.

For Q2 Earnings, Rite Aid Stock Must Bank on Positive Guidance

Rite Aid stock has a chance of recovering but the new CEO has plenty of work ahead. The company must grow prescription volumes and sales.

A New CEO is One Reason Why Rite Aid’s Long-Term Prospects are Improving

RAD stock looks tempting here in the midst of this lull, but what Rite Aid needs to do the most is the one thing that will be toughest to do.
The post New CEO Heyward Donigan Needs a Miracle to Revive Rite Aid Stock appeared first on InvestorPlace.

New CEO Heyward Donigan Needs a Miracle to Revive Rite Aid Stock

Enphase Energy

New Media Investment Group

Investors tried to weigh the various pressures affecting financial markets.

Why Rite Aid, Enphase Energy, and New Media Investment Group Jumped Today

Rite Aid (RAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rite Aid (RAD) Earnings Expected to Grow: Should You Buy?

Rite Aid (RAD) gains from increased immunizations and clinical pharmacy services, which are likely to continue. Decline in prescription reimbursement rates is a headwind.

Things You Must Know Prior to Rite Aid's (RAD) Q2 Earnings

With the RAD stock price down 95%, value investors might be intrigued. But there are better risk-adjusted plays than Rite Aid stock.

Why Rite Aid Stock Will Probably Underperform Alternatives

Oracle

An analyst downgrade and a set of uninspiring results drove down this pair of stock market mainstays.

These 2 Stocks Got Crushed by the Market Today -- Are They Now Buys?

An analyst's negative take is causing a sell-off for the retail pharmacy stock.

Why Rite Aid Stock Is Sinking Today.

As with most investments, the future of Rite Aid stock depends on millennials. Here, new Rite Aid CEO Heyward Donigan has both an opportunity as well as significant risks.

For Rite Aid Stock, Everything Depends on Millennials

Despite its cheap price, Rite Aid stock is hardly what you would call a discount. Instead, it’s a junk equity that you should steer clear from, considering that it doesn’t have an Amazon Counter-like catalyst in the foreseeable future.

Even After Recent Gains Rite Aid Stock Is Still Underweight

RAD stock is coming off of its best seven-day stretch in five years, but this rally may mean nothing in Rite Aid's bigger picture.
The post It’s Still Too Risky to Bet on Rite Aid Stock appeared first on InvestorPlace.

It’s Still Too Risky to Bet on Rite Aid Stock

RAD stock has been in an awful downtrend... for 15 years.

With 3 New Growth Catalysts, Is Rite Aid Stock Finally a Buy?

Having been gutted in the markets over the years, Rite Aid stock appeals to risk-tolerant contrarians. However, there are other names with similar upside potential but with much more stable fundamentals.

Is Rite Aid Stock the Best Play Under $6?

Rite Aid stock is not for the faint of heart, but RAD stock could surprise the critics and enrich the intrepid.
The post Rite Aid Stock Is Risky but Could Pay Off appeared first on InvestorPlace.

Rite Aid Stock Is Risky but Could Pay Off

Deutsche Bank

Dillard's

The following companies have recorded losses on the stock market over the past several years and will likely continue to do so as sell-side analysts on Wall Street have issued underweight recommendation ratings.

Consider Selling Shares of These 3 Underperforming Stocks

The Amazon deal with Rite Aid has only made RAD stock temporarily interesting. But to sustain momentum, the pharmacy needs a much deeper partnership with the e-commerce giant.

Rite Aid Stock Continues to Fade into Irrelevance Despite Amazon

A unique Amazon partnership provides a glimmer of hope for RAD stock, but don't bet on that glimmer of hope until it gets brighter.

Don’t Count on Amazon to Save Rite Aid Stock Just Yet

Heyward Donigan isn't the reason RAD stock has tanked of late. But, if she doesn't appreciate where Rite Aid is wasting money, she may be the reason Rite Aid stock continues to lose ground.

News for Rite Aid Stock (RAD)